TCR and pMHC production
NY-ESO-1 156−157 APLs were synthesized by standard solid-phase chemistry on a multiple peptide synthesizer (Genosys) using F-moc for transient NH2-terminal protection. All peptides were > 90% pure, as indicated by analytical HPLC. HLA-A2 heavy chain (residues 1-278) with C-terminal BirA tag and β 2 -microglobulin were expressed as inclusion bodies in E.coli, refolded in vitro in the presence of synthesized NY-ESO-1 156−157 APLs, and purified using size-exclusion chromatography [1] . Purified pMHC was biotinylated in vitro by BirA enzyme (Avidity). Modified HLA-A2 was generated by replacing amino-acids that lie at a distance shorter than 6 angstroms from the 1G4 TCR, using information from the crystal structure of 1G4 TCR in complex with ESO-9C/HLA-A2 [2] . Amino-acid substitutions were introduced in HLA-A2 expressing plasmid using a QuickChange site directed mutagenesis kit (Stratagene). Modified HLA-A2 proteins were all refolded with the ESO-9V peptide since this peptide has been shown to have improved affinity for MHC [2] . The 1G4 TCR subunits, α and β, were expressed in E.coli as inclusion bodies, refolded in vitro, and purified using size exclusion chromatography (as described in [3] ).
T-cell stimulation by plate-bound pMHC
To obtain various levels of pMHC surface immobilization, serial dilutions of each pMHC (100 µg/ml -300 pg/ml) were incubated in wells of SigmaScreen streptavidin coated 96-well plates (Sigma) for 90 minutes at 4 • C. Two plates were prepared, the first used for the stimulation assay and the second was used to determine the levels of correctly folded plate-immobilized pMHC. For the cell stimulation assay, 5000 1G4 CTLs were incubated in pMHC coated plates for 4h at 37 • C and the concentration of released IFN-γ in the supernatants was measured by ELISA using the OptEIA Human IFN-γ ELISA set (BD Biosciences). EC 50 values for each ligand were obtained by fitting a sigmoid dose-response model to the data using Origin (OriginLab Corporation). Levels of active plate-immobilized pMHC were measured on the second plate by ELISA using the W6/32 mouse anti human MHC class I antibody specific for correctly folded pMHC in combination with HRP conjugated donkey anti-mouse IgG antibody (Jackson Immunoresearch). Measured EC 50 values for IFN-γ secretion were then corrected by a factor representing fold difference in pMHC immobilization levels compared to ESO-9V/A2, which was chosen as a reference pMHC.
Cytotoxicity assay
We used a Transporter Associated with Antigen Processing (TAP) deficient T2 cell line pulsed with ESO-9V APLs as target cells. As a consequence of a defect in antigen processing, the T2 cell line expresses low levels of short-lived pMHC [4] and the addition of exogenous peptides significantly increases pMHC surface expression [4] . Since the effect of exogenous peptides on MHC stabilization in T2 cells can be variable, we first analyzed the effect ESO-9V APLs have on the increase in HLA-A2 levels in T2 cells. 100 000 T2 cells were incubated with various concentrations of peptides for 3 hours, stained with 10 µl/ml FITC labeled anti-HLA-A2 antibody (BB7.2 clone, BD), and HLA-A2 expression levels were analyzed by FACS ( Figure S2D ). The peptide concentration yielding a 40% increase of correctly folded surface HLA-A2 (C 40% ) was determined for each peptide. Target cells were prepared by labeling 5000 T2-cells with 51 Cr (50 µCi/million cells) for 90 minutes at 37 • C, washing, and incubating for 1h at 37 • C with serial dilution of specific peptides, starting from determined C 40% concentration. The cytotoxicity assay was then performed by adding 5000 1G4 CTLs to target cells for 4h at 37 • C. Levels of released 51 Cr from lysed cells were measured using a Microbeta counter (PerkinElmer). The percent of specific lysis was calculated from 100 x ((experimental release -spontaneous release) / (maximal release -spontaneous release)). Maximal 51 Cr release was measured by lysing target cells in 5% Triton X-100 and spontaneous release was found by measuring 51 Cr release from control target cells that were incubated without peptides.
Correlating the T cell response to TCR-pMHC bond parameters
As in previous studies, we have used the concentration of pMHC required to induce half-maximal response (EC 50 ) as an indicator of pMHC potency and in what follows pMHC potency is the dependent variable, y. The parameters governing the TCR-pMHC bond (e.g. K D , k off , k on , ∆C p , etc) are the independent variables which we define as x. We begin by assuming a simple linear relationship between pMHC potency and the parameters governing the TCR-pMHC bond,
where b 0 and b 1 are model parameters. All data fitting is performed using the Matlab function lsqcurvefit. Using the sum of squared residuals (SSR) we compute the R 2 statistic, which is the square of the correlation coefficient in this simple linear model. Using standard methods we obtain a p-value for the null hypothesis that the parameter b 1 = 0 (i.e. small p-values indicate the model is significant). Briefly, p-values are computed by calculating an F-score that accounts for the number of data points and the number of fitted parameters (2 in this case). Table 1 in the main text summarizes this analysis. Significant correlations (p< 0.05) are obtained only with K D , k off , and k on . Significant correlations are observed with other quantities (e.g. t 1/2 , ∆G, etc) as they are derived from either K D or k off .
As described above, the measure of pMHC potency (y) is the concentration required to elicit halfmaximal IFN-γ secretion (EC 50 ). We have introduced error into the analysis by using EC 50 directly, instead of log 10 (EC 50 ) (which is obtained from data fitting), because we expect TCR-pMHC bond parameters to be directly correlated to EC 50 . The introduced error is expected to be small because EC 50 values span less than an order of magnitude. We have also fit the data for EC 50 directly (instead of log 10 (EC 50 )) and obtained similar values. Repeating all the calculations we find quantitative differences (e.g. lower R 2 values for all models) but conclusions are unchanged (not shown).
In a second assay of pMHC potency, a measure of cytotoxicity is implemented. In this assay the agonist pMHC is diluted by null pMHC and therefore we expect that the relevant correlate will be 1/EC 50 . However, we found that the residuals from data fits were not randomly distributed ( Figure S3A ) and the log-transform provided randomly distributed residuals ( Figure S3B ). We speculate that there may be a nonlinear relationship between the concentration of incubated peptide and the level of pMHC presented to T cells by APCs. We have therefore taken the measure of pMHC potency to be y = 1/log 10 (EC 50 ), which provides the largest R 2 values. We find quantitative differences when y = 1/EC 50 is used (mainly lower R 2 values) but conclusions are unchanged (not shown). k off =1.9s Table S1 : Biophysical and functional characterisation of 1G4 TCR interaction with pMHC variants. Binding affinity, kinetics and thermodynamics of 1G4 TCR to various peptide and MHC mutants were measured at 37°C by SPR ( Figure S1 ). Activation potency of each pMHC in IFN -γ release assay and cytotoxicity assay is presented by EC 50 value. Mean values of at least three independently performed experiments are shown ± standard error of mean (SEM).
